Comparison of 24-h Urine Protein, Urine Albumin-to-Creatinine Ratio, and Protein-to-Creatinine Ratio in IgA Nephropathy

Guizhen Yu1,2,3,4,5, Jun Cheng1,2,3,4,5*, Heng Li1,2,3,4,5, Xiayu Li1,2,3,4,5 and Jianghua Chen1,2,3,4,5*

1 Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China, 2 Key Laboratory of Kidney Disease Prevention and Control Technology, Zhejiang University, Hangzhou, China, 3 National Key Clinical Department of Kidney Diseases, Zhejiang University, Hangzhou, China, 4 Institute of Nephrology, Zhejiang University, Hangzhou, China, 5 The Third Grade Laboratory Under the National State, Administration of Traditional Chinese Medicine, Hangzhou, China

Background: Proteinuria is a strong risk factor for renal outcomes in IgA nephropathy. Random urine protein-to-creatinine ratio (PCR), random albumin-to-creatinine ratio (ACR), and 24-h urine protein excretion (24-h UP) have been widely used in clinical practice. However, the measurement which is the best predictor of long-term renal outcomes remains controversial. This study aimed to compare the three measurements in IgA nephropathy.

Methods: We conducted a retrospective study of 766 patients with IgA nephropathy. The associations among baseline ACR, PCR, and 24-h UP with chronic kidney disease (CKD) progression event, defined as 50% estimated glomerular filtration rate (eGFR) decline or end stage kidney disease (ESKD), were tested and compared.

Results: In this study, ACR, PCR, and 24-h UP showed high correlation ($r = 0.671–0.847$, $P < 0.001$). After a median follow-up of 29.88 (14.65–51.65) months, 51 (6.66%) patients reached the CKD progression event. In univariate analysis, ACR performed better in predicting the prognosis of IgA nephropathy, with a higher area under the receiver operating curve (ROC) curve than PCR and 24-h UP. After adjustment for traditional risk factors, ACR was most associated with composite CKD progression event [per log-transformed ACR, hazard ratio (HR): 2.82; 95% (95% CI): 1.31–6.08; $P = 0.008$].

Conclusions: In IgA nephropathy, ACR, PCR, and 24-h UP had a high correlation. ACR performed better in predicting the prognosis of IgA nephropathy.

Keywords: IgA nephropathy, protein-to-creatinine ratio (PCR), albumin-to-creatinine ratio (ACR), 24-h urine protein excretion (24-h UP), kidney disease progression

INTRODUCTION

IgA nephropathy is the most common primary glomerulonephritis worldwide and the main cause of end-stage kidney disease (ESKD) (1). IgA nephropathy presents a variable clinical course ranging from asymptomatic hematuria to rapidly progressive kidney failure (2, 3). Proteinuria is one of the symptoms and has been established to be a robust predictor of outcome in IgA nephropathy.
Three measurements are used for proteinuria evaluation in clinical practice: 24-h urine protein excretion (24-h UP), random urine protein-to-creatinine ratio (PCR), and random albumin-to-creatinine ratio (ACR). Despite being considered the “gold-standard” in therapeutic guidelines, 24-h UP is cumbersome to perform, inconvenient for patients, and subject to sample collection variability. ACR and PCR in random spot urine measurements are commonly used. Numerous studies have investigated the quantitative assessment of proteinuria by using ACR and PCR in kidney disease and other diseases involving proteinuria (4–6). However, studies have shown conflicting results regarding the correlation among ACR, PCR, and 24-h UP. Some studies have indicated poor correlations among ACR, PCR, and 24-h UP measurements (7), whereas others have found a high degree of correlation among these measurements and suggested that they are equivalent predictors of renal outcomes (8–11). Therefore, whether PCR and ACR could replace the traditional 24-h UP and which measurement of proteinuria is most associated with long-term renal outcome remain unclear.

In this study, we aimed to evaluate the relationships among ACR, PCR, and 24-h UP in IgA nephropathy, and examine the efficacy of the three measurements in predicting the prognosis in IgA nephropathy.

METHODS

Study Population

In this retrospective study, a total of 766 patients with biopsy-proven IgA nephropathy, diagnosed between 2002 and 2019, were selected from The First Affiliated Hospital, Zhejiang University School of Medicine. All participants were followed up for more than 6 months and had complete clinical data. Patients with secondary causes of IgA deposition, such as liver cirrhosis, systemic lupus, and IgA vasculitis, were excluded. Minimal change disease was excluded in order to ensure the homogeneity of this cohort (12).

The study was approved by the local ethics committees, and written informed consent was obtained from all participants.

Information of Clinical Manifestations

In our center, ACR, PCR, and 24-h UP were collected within the same time frame. Random spot urine measurements were used for the detection of ACR and PCR. ACR and PCR were calculated as spot urinary albumin concentration and urinary protein concentration divided by urinary creatinine concentration, respectively (9). In addition, 24-h urine samples were collected for 24-h UP analysis.

Information of ACR, PCR, and 24-h UP, as well as other clinical data, including sex, age, blood pressure, and serum creatinine at the time of kidney biopsy, were collected from medical records. The estimated glomerular filtration rate (eGFR) was calculated with the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (13). Hypertension was defined as systolic BP ≥140 mmHg and/or diastolic BP ≥90 mmHg. Mean arterial pressure (MAP) was calculated as the sum of diastolic BP plus one-third of the pulse pressure. Nephrotic syndrome was defined as a 24-h urinary protein level exceeding 3.5 g/d. Kidney failure was defined as eGFR <15 ml/min/1.73 m², dialysis, or transplantation. The composite kidney disease progression event was defined as kidney failure and/or 50% eGFR decline.

Whether long-term outcome differs in IgA nephropathy patients with proteinuria between 0.5 and 1.0 g/d compared to ≤0.5 g/d remains unclear (14). Therefore, we divided patients into three groups according to the proteinuria levels in ACR (g/g), PCR (g/g), and 24-h UP (g/d), as group 1: <0.5; group 2: 0.5–1.0; and group 3: ≥1.0.

Statistical Analyses

Normally distributed data were expressed as mean ± SD and compared with a t-test. Non-normally distributed variables were summarized as medians or interquartile ranges and compared with Mann–Whitney U test. Qualitative variables were described in ratios or percentages and analyzed with a Chi-squared test. The Cox regression model was used to analyze the relationship between parameters and kidney disease progression events. The receiver operating curve (ROC) was used to compare the performance of ACR, PCR, and 24-h UP in predicting the progress of kidney disease.

Baseline clinical characteristics of patients with IgA nephropathy.

| Characteristic | Value, n = 766 |
|---------------|---------------|
| **Baseline**  |               |
| Male sex      | 391 (51.04)   |
| Age, y        | 38.05 ± 11.75 |
| MAP, mmHg     | 94.28 ± 13.66 |
| Serum albumin, g/L | 39.19 ± 6.07 |
| 24 Proteinuria, g/d | 0.99 (0.49–2.05) |
| PCR, g/g      | 0.93 (0.49–1.82) |
| ACR, g/g      | 0.55(0.29–1.21) |
| eGFR, ml/min/1.73 m² | 83.70 ± 29.19 |
| BMI (kg/m²)   | 22.93 ± 3.30  |
| **CKD stages, n (%)** |         |
| 1             | 354 (46.21)   |
| 2             | 219 (28.59)   |
| 3             | 172 (22.45)   |
| 4             | 21 (2.74)     |
| **Oxford classification, n (%)** |     |
| M1            | 111 (14.49)   |
| E1            | 52 (6.79)     |
| S1            | 457 (59.66)   |
| T1–T2         | 91 (11.88)    |
| C1–C2         | 289 (37.73)   |
| **Follow-up and outcome** |       |
| Follow-up duration, mo | 29.88 (14.65–51.65) |
| 50% eGFR decline, % | 43 (5.61) |
| Kidney failure, % | 37 (4.83) |
| Composite outcome, % | 51 (6.66) |

Values for continuous variables are expressed as mean ± SD or median [interquartile range]; count (percentage) is used for categorical variables. The composite outcome was defined as a 50% eGFR decline or kidney failure.
the prognosis of IgA nephropathy. The cumulative incidence function method was used to evaluate the association between proteinuria and kidney disease progression events. Statistical analysis was performed in SPSS 24.0, Stata software 14.0, and GraphPad Prism 8.0. A value of $P < 0.05$ was considered significantly different.

RESULTS

Clinical Characteristics of IgA Nephropathy

A total of 766 patients with IgA nephropathy with a median follow-up of 29.88 (14.65–51.65) months were included in this study. The baseline characteristics of the participants are presented in Table 1. The cohort included 391 (51.04%) men with a mean age of 38.05 ± 11.75 years. At the time of renal biopsy, the MAP level was 94.28 ± 13.66 mmHg, and the median eGFR was 83.70 ± 29.19 ml/min/1.73 m². The baseline 24-h UP, PCR, and ACR were 0.99 (0.49–2.05) g/d, 0.93 (0.49–1.82) g/g, and 0.55 (0.29–1.21) g/g, respectively. In total, 51 (6.66%) patients reached composite kidney disease progression events, including 37 (4.83%) kidney failure events.

Correlation Among ACR, PCR, and 24-h UP

As shown in Figure 1, a high degree of correlation was observed among ACR, PCR, and 24-h UP. PCR and 24-UP showed the best correlation ($r = 0.847, P < 0.001$), followed by PCR and ACR ($r = 0.716, P < 0.001$), and the correlation between ACR and 24-UP was lowest ($r = 0.671, P < 0.001$). The conversion coefficients between PCR and ACR, and 24-h UP and ACR were 0.84 and 0.96, respectively, which means that PCR multiplied by 0.84 equals the value of ACR, and 24-h UP multiplied by 0.96 equals the value of ACR.

ACR, PCR, 24-h UP, and Disease Severity and Progression in IgA Nephropathy

We analyzed the correlation between ACR, PCR, and 24-h UP at the time of renal biopsy with the severity of IgA nephropathy, and found these three measurements all correlated with chronic kidney disease (CKD) stage, hypertension, and Oxford E and T lesions. Patients with higher levels of 24-UP, PCR, and ACR showed severe CKD stage, hypertension, and Oxford E and T lesions (Table 2).

In unadjusted Cox models, 24-h UP, ACR, and PCR were associated with composite kidney disease progression events. The value of ACR was highest [24-h UP: hazard ratio (HR), 3.70; 95% CI: 1.96–6.99; $P < 0.001$; PCR: HR, 3.65; 95% CI: 1.94–6.88; $P < 0.001$; ACR: HR, 3.92; 95% CI: 2.22–6.94; $P < 0.001$]. After adjustment for the traditional risk factors of age, sex, MAP, eGFR, and Oxford classification (MEST-C scores), ACR had the highest HR value, compared with PCR and 24-h UP (ACR: HR, 2.82; 95% CI: 1.31–6.08; 24-h UP: HR, 2.75; 95% CI: 1.17–6.47; PCR: HR, 2.50; 95% CI:1.06–5.91) (Table 3).

After dividing patients into three groups according to the proteinuria levels, we found that in ACR, patients with proteinuria <0.5 had the best prognosis, although the difference was not statistically significant ($P = 0.238$), and this was followed by proteinuria 0.5–1.0, while patients with proteinuria ≥1.0 had the poorest prognosis. In terms of PCR and ACR, proteinuria <0.5 performed similar to 0.5–1.0 in long-term outcome survival curve (PCR: $P = 0.621$; 24-h UP: $P = 0.434$) (Figure 2).

To compare the performance of ACR, PCR, and 24-h UP in predicting renal outcome, we used ROC curve analysis, and the area under the ROC curves (AUC) was calculated. The AUC values and 95% CI of 24-h UP, ACR, and PCR were 0.71 (0.64–0.79), 0.74 (0.67–0.81), and 0.72 (0.65–0.80), respectively. Among these indicators, ACR had the highest AUC (Figure 3A). Results

![Figure 1](https://example.com/image1.png)
TABLE 2 | Correlation between 24-h urinary protein excretion (24-h UP), PCR, and ACR and severity of IgA nephropathy.

| Characteristics | 24-h UP (g/d) | PCR (g/g) | ACR (g/g) |
|-----------------|--------------|-----------|-----------|
|                  | p            | p         | p         |
| CKD stage       |              |           |           |
| 1               | 0.82 (0.43, 1.60) | 0.83 (0.43, 1.53) | 0.46 (0.23, 0.98) |
| 2               | 1.01 (0.49, 2.08) | 0.84 (0.47, 1.56) | 0.49 (0.29, 0.95) |
| 3               | 1.48 (0.60, 3.15) | 1.24 (0.69, 2.54) | 0.83 (0.39, 1.96) |
| 4               | 3.15 (1.58, 4.31) | 2.90 (1.47, 4.06) | 1.61 (0.87, 3.01) |
| Hypertension    |              |           |           |
| With            | 1.54 (0.68, 2.72) | 1.310 (0.60, 2.15) | 0.78 (0.41, 1.45) |
| Without         | 0.86 (0.46, 1.71) | 0.84 (0.43, 1.63) | 0.47 (0.27, 1.08) |
| Oxford classification |         |           |           |
| M lesion        | 0.092 (0.025, 0.175) | 0.09 (0.022, 0.168) | 0.113 (0.063, 0.164) |
| 1               | 1.10 (0.58, 2.37) | 1.00 (0.64, 2.05) | 0.63 (0.31, 1.40) |
| 0               | 0.97 (0.48, 2.00) | 0.92 (0.47, 1.80) | 0.53 (0.28, 1.20) |
| E lesion        |              |           |           |
| 1               | 2.11 (0.82, 5.67) | 2.24 (0.84, 4.21) | 1.11 (0.39, 2.41) |
| 0               | 0.95 (0.48, 1.91) | 0.89 (0.47, 1.70) | 0.53 (0.28, 1.14) |
| S lesion        | 0.667 (0.355, 1.288) | 0.403 (0.210, 0.791) | 0.401 (0.203, 0.779) |
| 1               | 0.99 (0.51, 1.91) | 0.94 (0.54, 1.79) | 0.51 (0.31, 1.06) |
| 0               | 0.97 (0.46, 2.26) | 0.88 (0.42, 1.91) | 0.61 (0.25, 1.41) |
| T lesion        |              |           |           |
| 1 or 2          | 1.93 (0.67, 3.71) | 1.70 (0.73, 2.79) | 0.97 (0.42, 2.07) |
| 0               | 0.94 (0.48, 1.85) | 0.88 (0.47, 1.66) | 0.51 (0.28, 1.11) |

TABLE 3 | Association of 24-h urinary protein excretion and PCR with composite kidney disease progression.

| Hazard ration, 95% confidence interval and P-value | Unadjusted | Model 1 | Model 2 | Model 3 |
|--------------------------------------------------|------------|---------|---------|---------|
| Lg (24-h UP)                                     | 3.70 (1.96–6.99) | 3.54 (1.85–6.76) | 1.71 (0.78–3.73) | 2.75 (1.17–6.47) |
|                                                  | <0.001     | <0.001  | 0.178   | 0.021   |
| Lg (PCR)                                         | 3.65 (1.94–6.88) | 3.36 (1.73–6.49) | 1.68 (0.75–3.72) | 2.50 (1.06–5.91) |
|                                                  | <0.001     | <0.001  | 0.205   | 0.037   |
| Lg (ACR)                                         | 3.92 (2.22–6.94) | 3.69 (2.05–6.66) | 2.33 (1.08–5.05) | 2.82 (1.31–6.08) |
|                                                  | <0.001     | <0.001  | 0.032   | 0.008   |

A CKD progression event was defined as 50% eGFR or kidney failure. Model 1 was adjusted for sex and age; sex is expressed as a dichotomous variable. Model 2 was adjusted for covariates in Model 1 plus mean arterial pressure and baseline eGFR. Model 3 was adjusted for covariates in model 2 plus Oxford classification (MEST-C scores).

DISCUSSION

Proteinuria is a strong risk factor in predicting the prognosis of IgA nephropathy. ACR and PCR in random spot urine measurements and 24-h UP are commonly used to evaluate proteinuria in clinical practice. However, whether PCR or ACR might replace the traditional 24-h UP examination, and which measurement of proteinuria is the best predictor of long-term renal outcomes in IgA nephropathy remain unknown. In this study of 766 patients with IgA nephropathy, we found that ACR and PCR showed a high correlation with 24-h UP. After stratifying analyses by proteinuria at 3.5 g/d, we found that the correlations among ACR, PCR, and 24-h UP were similar to those in the overall study population. With respect to prediction of long-term renal outcome, defined as 50% eGFR decline or renal failure, ACR had the best correlation, compared with PCR and 24-h UP. Another key finding was that, in patients with nephrotic syndrome, serum albumin was found to be a tool for assessing the extent of proteinuria.

The "gold standard" method for evaluating proteinuria is quantifying the protein concentration in the urine for 24 h (8). However, 24-h UP evaluated with 24-h urine collection is troublesome and time consuming for patients, and sometimes involves errors that can affect the accuracy of the results (15–18). PCR and ACR in random spot urine measurements are two simple and fast methods for quantitative assessment of...
FIGURE 2 | Kaplan-Meier kidney survival curves for patients with IgA nephropathy, according to 24-h urine protein (A), albumin-to-creatinine ratio (B), and PCR (C). Time zero was the time of kidney biopsy. The divisions among the three groups were based on the levels of proteinuria: group 1: ≤0.5, group 2: 0.5–1.0, group 3: ≥1.0.

FIGURE 3 | Receiver operating characteristic (ROC) (A) and time-dependent ROC (B) curves with the composite outcome as the status variable. The AUCs were compared among ACR, PCR, and 24-h UP using ROC and time-dependent ROC curves. Among these indicators, ACR had the highest AUC.

urine protein excretion, which are commonly used in clinical practice. However, several reports comparing PCR, ACR, and 24-h UP have yielded conflicting results. Some studies have shown that PCR and ACR have a poorer correlation in lower ranges of proteinuria (19). Multiple studies have indicated that ACR is superior to PCR in the consistency, sensitivity, and quality of the approach for early detection and management of CKD (20, 21). Jinn-Yuh Guh has reported that ACR performs better in patients with diabetes, whereas PCR performs better in non-diabetic patients (22). In contrast, a study from the UK has demonstrated that PCR is more sensitive than ACR in patients with proteinuria <0.5 g/d and <1.0 g/d (23). Many studies have established that ACR and PCR display a strong linear correlation with 24-h UP (21, 24, 25). In a UK cohort of 1,676 patients with CKD over 3.5 years of follow-up, ACR and PCR have been found to perform as well as 24-h UP in predicting renal outcome in patients with CKD; however, the PCR and ACR were derived from aliquots of 24-h urine samples rather than random spot urine measurements in that study (11). Given the conflicting results, the recommendations vary among guidelines. In 2012, the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommended ACR over PCR measurement, partly because of sample-to-sample variation, the composition of urine protein, and inter-laboratory variation in PCR measurement. Interestingly, despite the limitations of PCR measurement, PCR has been found to be similar to ACR in its association with complications in CKD (26). The recently published KDIGO guidelines recommend that 24-h UP or PCR should be measured when therapeutic decisions about using high-risk medications are being made on small changes in proteinuria. PCR from an intended 24-h UP collection that is at least 50% complete has been shown to accurately reflect 24-h UP (27, 28). Some recommendations have advocated using ACR to replace PCR measurement (21, 29, 30), whereas others have suggested continuing the use of PCR.

In this much larger sample study with 766 patients with IgA nephropathy, we confirmed that PCR, ACR, and 24-h UP displayed a strong linear relationship. Compared with PCR and 24-h UP, ACR performed best in predicting the long-term renal outcomes, defined as a 50% eGFR decline or ESKD in IgA nephropathy. To our knowledge, only one prior study has compared different measurements of proteinuria in IgA nephropathy. In that study, similarly to our findings, ACR, PCR, and 24-h UP showed a good correlation, and all three measurements of proteinuria were associated with poor renal outcome, defined as 30% eGFR decline, ESKD, or death in a cohort study with 438 patients with IgA nephropathy.
Our study confirmed the previous results in a larger sample with 766 patients with IgA nephropathy and defined a robust renal outcome defined as 50% eGFR decline or renal failure. Furthermore, we found that in patients with nephrotic syndrome, the serum albumin levels were negatively correlated with proteinuria, which is in agreement with a prior hypothesis that monitoring serum albumin levels in nephrotic patients might also be a valuable tool to indirectly assess the extent of proteinuria (27). However, nephrotic syndrome is uncommon in IgA nephropathy and was found in only 96 (12.14%) patients in our center. Therefore, further confirmation in larger samples is needed.

Whether long-term outcome differs in patients with proteinuria between 0.5 and 1.0 g/d compared with <0.5 g/d remains unknown (14). In our study, patients with proteinuria <0.5 g/d had better prognoses than those with proteinuria between 0.5 and 1.0 g/d only in proteinuria measurement of ACR; however, for PCR and 24-h UP, patients with proteinuria <0.5 g and 0.5–1.0 g had similar prognosis. A recent study has reported similar HR values for risk of ESRD for proteinuria <0.5 g/d and 0.51–1.0 g/d in 921 participants with IgA nephropathy, which is in agreement with our findings (31). Whether lowering proteinuria <0.5 g/d is renoprotective still need further confirmation.

The strength of this study includes the large sample size, including many renal outcome events observed in IgA nephropathy. However, this study also has several limitations. First, our patients included only those with IgA nephropathy; thus, we cannot extrapolate our findings to other patients with CKD. Second, all patients in our study were from a single center and were from a single ethnic group, and more than 90% of patients received steroids, renin angiotensin aldosterone system inhibitors (RAASis), and other immunosuppressant therapy during follow-up, and therefore, we did not include the use of immunosuppressant and RAASI in the analysis. According to the recently published 2021 KDIGO Guideline, rapidly progressive IgA nephropathy was defined as 50% eGFR decline within 3 months. However, in our study, all participants were followed up for more than 6 months, and there were no rapidly progressive IgA nephropathy patients. This is another limitation in our study (32). Thus, the results still need further confirmation in a more diverse cohort.

In conclusion, in this study, we demonstrated that ACR, PCR, and 24-h UP displayed a good correlation. ACR and PCR were comparable to 24-h UP in predicting the prognosis of IgA nephropathy.

Data Availability Statement
The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

Author Contributions
JCheng and JChen are the guarantors of the integrity of the entire study and contributed to the study concepts and study design. GY contributed to data acquisition and interpretation, clinical studies, and manuscript preparation. HL and XL contributed to manuscript editing. JChen contributed to the manuscript review. All authors have contributed significantly. All authors contributed to the article and approved the submitted version.

Funding
This study was supported by grant LY19H050007 from Zhejiang Natural Science Foundation and grant 2016KYA087 Zhejiang Medical and Health Science and Technology Project.

Supplementary Material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2022.809245/full#supplementary-material

References
1. Donadio JV, Grande JP. IgA nephropathy. N Engl J Med. (2002) 347:738–48. doi: 10.1056/NEJMra020109
2. Coppo R, Amore A. Aberrant glycosylation in IgA nephropathy (IgAN). Kidney Int. (2004) 65:1544–7. doi: 10.1111/j.1523-1755.2004.05407.x
3. Novak J, Tomana M, Kilian M, Coward L, Kulhavy R, Barnes S, et al. Heterogeneity of O-glycosylation in the hinge region of human IgA1. Mol Immunol. (2000) 37:1047–56. doi: 10.1016/S0161-5890(01)00019-0
4. Forlemu A, Menanga A, Ashuntantang G, Kingue S. Urinary protein excretion is associated with left ventricular hypertrophy in treatment-naive hypertensive patients in an african hospital setting. Cardiothorac Med. (2013) 3:57–62. doi: 10.1159/000349938
5. Cade TJ, Gilbert SA, Polyakov A, Hotchin A. The accuracy of spot urinary protein-to-creatinine ratio in confirming proteinuria in pre-eclampsia. Aust N Z J Obstet Gynaecol. (2012) 52:179–82. doi: 10.1111/j.1479-828X.2011.01409.x
6. Touma Z, Urowitz MB, Ibañez D, Gladman DD. Time to recovery from proteinuria in patients with lupus nephritis receiving standard treatment. J Rheumatol. (2014) 41:688–97. doi: 10.3899/jrheum.130005
7. Hogan MC, Reich HN, Nelson P, Adler SG, Catran DC, Appel GB, et al. The relatively poor correlation between random and 24-hour urine protein excretion in patients with biopsy-proven glomerular diseases. Kidney Int. (2016) 90:1080–9. doi: 10.1016/j.kint.2016.06.020
8. Kamińska J, Dymicka-Piekarska V, Tomaszewska J, Matowicka-Karna J, Koper-Lenkiewicz OM. Diagnostic utility of protein to creatinine ratio (P/C ratio) in spot urine sample within routine clinical practice. Crit Rev Clin Lab Sci. (2020) 57:345–64. doi: 10.1080/10408363.2020.1723487
9. Gaspari F, Perico N, Remuzzi G. Timed urine collections are not needed to measure urine protein excretion in clinical practice. Am J Kidney Dis. (2006) 47:1–7. doi: 10.1053/j.ajkd.2005.10.014
10. Miller WG, Bruns DE, Hortin GL, Sandberg S, Aakre KM, McQueen MJ, et al. Current issues in measurement and reporting of urinary albumin excretion. Clin Chem. (2009) 55:24–38. doi: 10.1373/clinchem.2008.106567
11. Methven S, MacGregor MS, Traynor JP, Hair M, O’Reilly DS, Deighan CJ. Comparison of urinary albumin and urinary total protein as
predictors of patient outcomes in CKD. Am J Kidney Dis. (2011) 57:21–8. doi: 10.1053/j.ajkd.2010.08.009
12. Herlitz LC, Bomback AS, Stokes MB, Radhakrishnan J, D’Agati VD, Markowitz GS. IgA nephropathy with minimal change disease. Clin J Am Soc Nephrol. (2014) 9:1033–9. doi: 10.2215/CJN.11951113
13. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF III, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. (2009) 150:604–12. doi: 10.7326/0003-4819-150-9-20090505-00006
14. Chapter 10: immunoglobulin A nephropathy. Kidney Int Suppl. (2012) 2:209–17. doi: 10.1038/kisp.2012.23
15. Ruggenenti P, Gaspari F, Perna A, Remuzzi G. Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes. BMJ. (1998) 316:504–9. doi: 10.1136/bmj.316.7130.504
16. Coté AM, Firoz T, Mattman A, Lam EM, von Daelenzen P, Magee LA. The 24-hour urine collection: gold standard or historical practice? Am J Obstet Gynecol. (2008) 199:625.e1–6. doi: 10.1016/j.ajog.2008.06.009
17. Patil P, Shah V, Shah B. Comparison of spot urine protein creatinine ratio with 24 hour urine protein for estimation of proteinuria. J Assoc Physicians India. (2014) 62:406–10.
18. Price CP, Newall RG, Boyd JC. Use of protein:creatinine ratio measurements on random urine samples for prediction of significant proteinuria: a systematic review. Clin Chem. (2005) 51:1577–86. doi: 10.1373/clinchem.2005.049742
19. Kim SM, Lee CH, Lee JP, Oh YK, Kim YS, Kim S, et al. The association between albumin to creatinine ratio and total protein to creatinine ratio in patients with chronic kidney disease. Clin Nephrol. (2012) 78:346–52. doi: 10.5414/CN107507
20. Lamb EJ, MacKenzie F, Stevens PE. How should proteinuria be detected and measured? Ann Clin Biochem. (2009) 46:205–17. doi: 10.1258/acb.2009.009007
21. Zhao YF, Zhu L, Liu LJ, Shi SF, Lv JC, Zhang H. Measures of urinary protein and albumin in the prediction of progression of IgA nephropathy. Clin J Am Soc Nephrol. (2016) 11:947–55. doi: 10.2215/CJN.10150915
22. Guh JY. Proteinuria versus albuminuria in chronic kidney disease. Nephrology. (2010) 15(Suppl. 2):S3–6. doi: 10.1111/j.1440-1797.2010.01314.x
23. Methven SN, MacGregor MS, Traynor JP, O’Reilly DS, Deighan CJ. Assessing proteinuria in chronic kidney disease: protein-creatinine ratio versus albumin-creatinine ratio. Nephrol Dial Transplant. (2010) 25:2991–6. doi: 10.1093/ndt/gfq140
24. Guy M, Borzomato JK, Newall RG, Kalra PA, Price CP. Protein and albumin-to-creatinine ratios in random urines accurately predict 24 h protein and albumin loss in patients with kidney disease. Ann Clin Biochem. (2009) 46:468–76. doi: 10.1258/acb.2009.009001
25. Ginberg JM, Chang BS, Matarrese RA, Garella S. Use of single voided urine samples to estimate quantitative proteinuria. N Engl J Med. (1983) 309:1543–6. doi: 10.1056/NEJM198312223090203
26. Fisher H, Hsu CY, Vittinghoff E, Lin F, Bansal N. Comparison of associations of urine protein-creatinine ratio versus albumin-creatinine ratio with complications of CKD: a cross-sectional analysis. Am J Kidney Dis. (2013) 62:1102–8. doi: 10.1053/j.ajkd.2013.07.013
27. Floge J, Barbour SJ, Cattrann DC, Hogan JJ, Nachman PH, Tang SCW, et al. Management and treatment of glomerular diseases (part 1): conclusions from a Kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int. (2019) 95:268–80. doi: 10.1016/j.kint.2018.10.018
28. Hebert LA, Birmingham DJ, Shihgam G, Rovin B, Nagaraja HN, Yu CY. Random spot urine protein/creatinine ratio is unreliable for estimating 24-hour proteinuria in individual systemic lupus erythematosus nephritis patients. Nephron Clin Pract. (2009) 113:e177–82. doi: 10.1159/000232359
29. Montañés Bermúdez R, Gracia García S, Pérez Surribas D, Martínez Castelao A, Bover Sanjuán J. Consensus document. Recommendations on assessing proteinuria during the diagnosis and follow-up of chronic kidney disease. Nefrologia. (2011) 31:331–45. doi: 10.3265/Nefrologia.pre2011Jan.103087
30. Johnson DW, Jones GR, Mathew TH, Ludlow MJ, Chadban SJ, Usherwood T, et al. Chronic kidney disease and measurement of albuminuria or proteinuria: a position statement. Med J Aust. (2012) 197:224–5. doi: 10.5694/mja11.11468
31. Ai Z, Zhou Q, Huang F, Yang Q, Yu X. Long-term renal outcomes of IgA nephropathy presenting with different levels of proteinuria. Clin Nephrol. (2020) 94:290–6. doi: 10.5414/CN110192
32. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int. (2021) s1–276. doi: 10.1016/j.kint.2021.05.021

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.